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Abstract
The c-Myb transcription factor is a critical regulator of proliferation and stem cell differentiation, and mutated alleles of c-
Myb are oncogenic, but little is known about changes in c-Myb activity during the cell cycle. To map the association of c-
Myb with specific target genes during the cell cycle, we developed a novel Fix-Sort-ChIP approach, in which asynchronously
growing cells were fixed with formaldehyde, stained with Hoechst 33342 and separated into different cell cycle fractions by
flow sorting, then processed for chromatin immunoprecipitation (ChIP) assays. We found that c-Myb actively repositions,
binding to some genes only in specific cell cycle phases. In addition, the specificity of c-Myb is dramatically different in small
subpopulations of cells, for example cells in the G2/M phase of the cell cycle, than in the bulk population. The repositioning
of c-Myb during the cell cycle is not due to changes in its expression and also occurs with ectopically expressed, epitope-
tagged versions of c-Myb. The repositioning occurs in established cell lines, in primary human CD34+ hematopoietic
progenitors and in primary human acute myeloid leukemia cells. The combination of fixation, sorting and ChIP analysis
sheds new light on the dynamic nature of gene regulation during the cell cycle and provides a new type of tool for the
analysis of gene regulation in small subsets of cells, such as cells in a specific phase of the cell cycle.
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Introduction
The c-Myb protein is a DNA binding transcription factor that
regulates the expression of specific target genes [1]. Mutations that
convert the normal c-Myb protein into an oncogenic transforming
protein also change the spectrum of genes that it regulates [2,3].
Several types of evidence suggest that the c-Myb transcription
factor may be regulated during the cell cycle. For example, c-Myb
interacts with Cyclin D1 [4] and with cyclin-dependent kinases
CDK4 and CDK6 [5]. In addition, c-Myb has been shown to
regulate the CCNB1 gene, which encodes the cell cycle regulator
Cyclin B1 [6], and has been implicated in the regulation of the
CCNE1 gene, which encodes Cyclin E1 [7]. The c-Myb
transcription factor is responsible for the proper regulation of
hematopoiesis [8] and inhibition or ablation of c-myb gene
expression blocks hematopoietic cell differentiation in vitro [9]
and leads to a loss of hematopoietic cells in animals [10].
Mutations in protein interaction sites in c-Myb lead to defects in
hematopoietic stem cell differentiation [11], and change the
specificity of c-Myb, allowing it to regulate different sets of target
genes [2,3,12]. Thus, oncogenic mutations could alter the activity
of c-Myb, a transcription factor that is normally regulated during
the cell cycle.
But how would cell cycle regulation of c-Myb manifest itself? At
least two mechanisms have been described for transcription factor
regulation during the cell cycle. One example is E2F transcription
factors, which are inhibited during the G1 phase of the cell cycle
by bound Retinoblastoma tumor suppressor protein. In S phase,
Cyclin D1/CDK4 phosphorylation of Retinoblastoma triggers its
removal and leads to the activation of E2F target genes [13]. In
contrast, receptor-activated signaling cascades lead to activation of
kinases like Akt, which phosphorylate FOXO transcription factors,
leading to their migration to and sequestering in the cytoplasm,
preventing them from regulating the expression of genes encoding
cell cycle regulators [14]. Both of these examples are ways in
which transcription factors change activity or localization, but not
specificity, during the cell cycle.
We set out to monitor the activity of c-Myb and determine
whether it is regulated during the cell cycle. We opted to use
chromatin immunoprecipitation to follow the association of c-Myb
with different gene promoters in cultures of human cells that were
progressing normally through the cell cycle. This approach
allowed us to fix the proteins with formaldehyde while the cells
were still in the culture dish, locking in the results before the cells
were manipulated in any way. Then the cells were harvested,
sorted into cell cycle stages and used for chromatin immunopre-
cipitation experiments. The results show that c-Myb undergoes
dramatic and dynamic repositioning onto different gene promoters
during the cell cycle, suggesting that complex mechanisms regulate
its specificity and activity in a time-dependent manner, and
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during the cell cycle.
Results
Hydroxyurea and nocodazole cause dramatic changes in
c-Myb expression and activity
We were faced with a dilemma when we set out to measure the
activities of c-Myb during different phases of the cell cycle, since
conventional methods of measuring transcription factor activity are
poorly suited to such studies. For example, reporter gene assays
have been used to measure c-Myb activity, but rely on the
production of reporter enzymes, which must accumulate and could
have long half-lives. Similarly, target gene mRNAs could be present
long after c-Myb did its work. We settled on the approach of using
chromatin immunoprecipitation (ChIP) assays to detect promoters
c-Myb was associated with during specific phases of the cell cycle.
We focused on two cell cycle-dependent target genes for our study.
The CCNB1 gene, which encodes Cyclin B1, was recently shown to
be a bona fide c-Myb target gene in hematopoietic cells [6]. The
CCNE1 gene, encoding Cyclin E1, has been implicated as a c-Myb
target through co-localization and knockdown studies in several cell
types [7]. Both of the cyclin genes are expected to be regulated in a
cell cycle-specific fashion, so should be excellent models for
following changes in c-Myb activity. Both genes have been
confirmed as bona fide c-Myb targets through genome-wide
promoter tiling array experiments (Quintana AM, Liu F, O’Rourke
JP and Ness SA, manuscript submitted), which have been deposited
in the NCBI GEO database (accession number: GSE18706).
Initial ChIP assays using asynchronously growing Jurkat T-cells
showed c-Myb protein associated with the promoter of the
CCNB1 genes, but not with the CCNE1 gene promoter
(Figure 1A). To follow changes during the cell cycle, we treated
the cells with hydroxyurea (HU) or nocodazole (NOC) for 18 hr to
arrest the cells in early S phase or G2/M, respectively (Figure 1B).
However, when ChIP assays were performed on the drug-treated
cells, c-Myb could not be detected at either the CCNB1 or
CCNE1 promoters in the hydroxyurea treated cells (Figure 1C,
gray bars), although c-Myb was associated with the CCNE1
promoter in the nocodazole-treated cells (Figure 1C, black bars).
Thus, the cells treated with hydroxyurea or nocodazole gave
results in the ChIP assay that were completely different than the
asynchronously growing cells, suggesting that c-Myb protein
activity could be cell cycle regulated.
Next we analyzed these cell populations for c-Myb protein
expression by Western blot. We found that c-Myb protein levels
were comparable in the asynchronously growing and hydroxy-
urea-treated cells, but were dramatically reduced in the cells
treated with nocodazole (Figure 1D). We obtained this result in
multiple experiments and using two different anti-c-Myb antibod-
ies, suggesting that nocodazole treatment leads to a dramatic
decrease in c-Myb protein levels in Jurkat T cells. Note: Although
the Western blot shown in Figure 1D gives the impression that c-
Myb protein is absent in the nocodazole-treated cells, c-Myb
protein is detectable in longer exposures (not shown). The residual
protein is presumably responsible for the positive ChIP results in
the nocodazole-treated cells (Figure 1C). The stability and
degradation of c-Myb protein has been reported to be controlled
by multiple different regulatory pathways [15–18]. Our results
using hyrdroxyurea- and nocodazole-treated cells suggest that
these pathways may be affected by the drug treatments or the cell
cycle. This makes the use of hydroxyurea and nocodazole
problematic for the study of c-Myb during the cell cycle, which
prompted us to develop a different approach.
The levels of c-Myb associated with chromatin remain
constant during the cell cycle
Our studies with the drug-treated cells showed dramatic
changes in c-Myb protein levels in the cells that were arrested in
G1, S and G2/M (Figure 1). However, those changes were in
conflict with our ChIP assay results, which showed that c-Myb
must be bound to at least some promoters in the G2/M phase of
the cell cycle. These conflicting results prompted us to develop a
different type of cell cycle assay that did not rely on drug
treatments. First, we tested whether asynchronously growing cells
could be fixed with formaldehyde, as for a ChIP assay, then
stained with Hoechst 33342 DNA content dye and subjected to
flow cytometric cell sorting. As shown in Figure 2A, the fixed
Jurkat cells gave a typical cell cycle profile when analyzed for DNA
content. We sorted the cells into G1, S and G2/M fractions, then
re-analyzed the sorted cells (Figure 2A, lower panel), which
showed that, although there was some overlap in the DNA content
of the sorted cells, the fractions were greatly enriched for cells in
the expected cell cycle stages.
Since c-Myb is a DNA-binding transcription factor, the active
fraction of the protein is presumed to be associated with chromatin.
Therefore, we determined the c-Myb protein levels that were
associated with chromatin during the different cell cycle stages. We
fixed and sorted an asynchronously growing culture of Jurkat cells
(Figure 2B), harvested the chromatin from equal numbers of fixed
cells from the G1, S or G2/M cell cycle fractions, then de-
crosslinked the samples and analyzed the recovered proteins by
Western blot using anti-c-Myb antibodies. As shown in Figure 2C,
all three cell cycle fractions contained the same amount of Histone
H4 (used here as a loading control) and very similar amounts of c-
Myb protein, suggesting that c-Myb protein expression, localization
and association with chromatin and DNA remained constant
throughout the cell cycle. This is an important result, which
contrasts sharply with the results we obtained with the drug-treated
cells. Our analysis using cells that were rapidly fixed and sorted
based on DNA content shows that the levels of c-Myb associated
with chromatin remain constant, suggesting that c-Myb could be
associated with and regulate target genes throughout the cell cycle.
Association of c-Myb with some target genes is cell cycle
stage specific
The results using the fixed and sorted cells (Figure 2) suggested
that we could extend that approach to analyze the association of c-
Myb with target genes in ChIP assays. With that in mind, we
developed the Fix-Sort-ChIP approach, in which asynchronously
growing cells were fixed with formaldehyde, stained and sorted
into cell cycle fractions as described in the previous section, then
the chromatin was recovered from equal numbers of sorted cells in
each cell cycle stage and processed for ChIP assays.
Using the Fix-Sort-ChIP approach, we tested the association of
c-Myb with the CCNB1 and CCNE1 gene promoters. The results
from one experiment, which are representative of many similar
ones, are shown in Figure 3. As shown in Figure 3A, c-Myb was
associated with the CCNB1 promoter in both G1 and G2/M, but
not in S phase cells. This is consistent with reports that c-Myb
regulates the CCNB1 gene in G2/M phase cells [6], but contrasts
markedly with the results obtained with the drug treated cells
(Figure 1C), which did not detect c-Myb at the CCNB1 promoter
in the cell cycle-arrested cells. Thus, the Fix-Sort-ChIP approach
appears to give better and more reliable cell cycle results than the
drug treatment experiments.
Although equal amounts of c-Myb protein are bound to
chromatin in all of the cell cycle phases (Figure 2D), the results in
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CCNE1 promoter in the G2/M phase of the cell cycle. This
association was not detected in the asynchronous cells (Figure 1A),
perhaps because the G2/M phase cells made up such a small
percentage of the total population.This isa striking result, suggesting
that c-Myb activity changes during the cell cycle, leading it to
associate with specific genes only in the G2/M phase. It also shows
that c-Myb has different activities in small subpopulations of cells,
which could be overlooked in a mixed population of cells. In this
case, the ChIP assays failed to detect c-Myb at the CCNE1 target
gene in asynchronous cells, but did so when cell sorting revealed the
differences in the G2/M subpopulation. Interestingly, c-Myb was
not associated with either of the cyclin genes in the S phase cells.
The cyclin genes are intimately related to control of the cell cycle,
so they could represent special cases of genes that are extraordi-
narily regulated during the cell cycle. Therefore, we also analyzed
the association of c-Myb with the CXCR4 gene promoter. The
CXCR4 gene encodes the receptor for the chemokine SDF-1 and
was identified as a c-Myb target gene in microarray studies [2,3,19],
but is not known to be cell cycle regulated. Using the Fix-Sort-ChIP
approach, we found c-Myb associated with the CXCR4 gene
promoterin both S phase and G2/M phase cells(Figure 3C). Thisis
an important result since it demonstrates that there is nothing
preventingc-Myb from being detected at targetgene promotersinS
phase cells. It also shows that CXCR4 may be a cell cycle regulated
gene, since c-Myb only binds the promoter in the cells that are
progressing through the cell cycle, either in S phase or G2/M.
The results shown in Figure 3 are representative of numerous
independent experiments, and have been reproduced using two
different anti-c-Myb antibodies that recognize different parts of the
protein. Therefore, we do not think the cell cycle phase-specific
results are likely to be due to epitope masking or other antibody-
related effects. Taken together, these results suggest that c-Myb
redistributes to different target gene promoters in different phases
of the cell cycle, suggesting that its specificity is regulated in a
dynamic and cell cycle dependent manner.
Association of c-Myb with target genes correlates with
their expression
The results of the ChIP assays shown above suggest that c-Myb
is only associated with some target genes at specific times in the
cell cycle. We next tested whether the expression of these target
Figure 1. Hydroxyurea and nocodazole affect c-Myb levels and
activity. (A) Conventional ChIP assay with Jurkat cells. Asynchronously
growing Jurkat cells were fixed and subjected to ChIP analysis to
determine whether c-Myb was associated with the CCNB1 and CCNE1
promoters. The results are plotted as fold enrichment compared to
control IgG as measured using Quantitative real-time PCR (QPCR). Error
bars show the standard deviation of triplicate QPCR assays. The results
are representative of several independent experiments. (B) Effects of
hydroxyurea (HU) and nocodazole (NOC). Jurkat cells were treated 16–
18 hr with the cell cycle blockers HU or NOC to arrest the cells in S
phase or G2/M, respectively, then samples were stained with Hoechst
33342 and the cell cycle profiles were compared to untreated,
asynchronously (Asyn) growing cells by flow cytometry. The histograms
show cell number vs DNA content, and the G1, S and G2/M portions of
the diagrams are labeled. (C) ChIP assay with HU and NOC treated cells.
Jurkat cells treated 16–18 hr with HU or NOC were harvested, fixed and
processed for ChIP assays, using anti-Myb antibodies. The association of
c-Myb with the CCNB1 or CCNE1 promoters was assessed by QPCR, as
described above. Results are plotted as fold enrichment compared to
control IgG and error bars show standard deviation of triplicate QPCR
assays. These results are representative of several independent
experiments. (D) Expression of c-Myb protein. Total cell extracts from
Jurkat cells growing asynchronously (Asyn) or treated with NOC or HU
were analyzed by Western blot for expression of c-Myb protein. The
blot was treated with one anti-Myb antibody, then stripped and re-
probed with a different anti-c-Myb antibody and finally stripped and re-
probed for beta-actin as a protein loading control. These results are
representative of several independent experiments. Note: All of the
experiments in this figure were performed at least three times each. The
results shown are from a single experiment but are representative of all
the trials.
doi:10.1371/journal.pone.0017362.g001
Repositioning of c-Myb during the Cell Cycle
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17362genes correlated with the binding of c-Myb to their promoters.
However, because isolating RNA from formaldehyde-fixed cells
was not possible, we used unfixed cells for the gene expression
assays, and performed the sorting as quickly as possible to preserve
the RNA, so we could only harvest enough cells to produce G1
and combined S/G2/M populations. Briefly, asynchronously
growing Jurkat T cells were stained and sorted into G1 or
combined S/G2/M fractions as described above, but without the
formaldehyde fixation that interfered with recovery of RNA. The
sorted cells were immediately processed to purify the RNA, which
was analyzed by quantitative real-time PCR. As shown in
Figure 4A, CCNB1 mRNA was detected at similar levels in the
asynchronously growing cells and in the S/G2/M fraction, but
was about 5-fold lower in the G1 phase cells, a result which
correlates nicely with the ChIP data shown in Figure 3A, where
association of c-Myb with the CCNB1 promoter was several fold
higher in the G2/M phase cells compared to the G1 phase cells.
The results with the CCNE1 mRNA were also consistent with the
results of the ChIP experiments. The S/G2/M phase cells
contained more than 40-fold more CCNE1 mRNA than the
asynchronous population or the G1 phase cells (Figure 4B),
suggesting that the CCNE1 gene is only expressed in the S/G2/M
phase cells, when c-Myb is bound to its promoter. In contrast, the
CXCR4 mRNA was found at similar levels in asynchronously
growing cells and in the G1 and S/G2/M fractions (Figure 4A).
This could be because expression of the CXCR4 mRNA is
independent of c-Myb, because the CXCR4 gene is regulated by
c-Myb in some cell cycle phases and by other, unknown
transcription factors in G1 phase cells (where c-Myb is not bound
to the CXCR4 gene promoter) or because the CXCR4 mRNA is
stable enough that its steady-state levels do not change significantly
during the cell cycle. This is supported by flow cytometric analysis
using anti-CXCR4 antibodies showing that CXCR4 cell surface
expression remains constant during the cell cycle in Jurkat cells
(data not shown). Taken together, our results suggest that the cell
cycle-dependent expression of the CCNB1 and CCNE1 genes
correlate with the binding of c-Myb to their promoters, but the
results with the CXCR4 gene remain inconclusive.
Ectopically expressed c-Myb is also retargeted during the
cell cycle
The control of c-Myb protein expression is complex and
involves many types of regulation, including controls of c-myb gene
expression and estrogen regulated RNA elongation [20,21],
complex patterns of alternative RNA splicing [22] and several
regulatory microRNAs that interact with the 39-untranslated
region (39-UTR) of the c-myb mRNA [23–27]. It was possible, for
example, that our ChIP assays were detecting different variants of
c-Myb, produced through alternative RNA splicing, that bound to
different promoters. To address these potential mechanisms, we
generated an N-terminal FLAG epitope-tagged derivative of c-
Myb, expressed from a lentiviral vector, which we used to
transduce the Jurkat T-cells so that it was stably expressed. The
lentivirus vector lacked the normal c-myb 39-UTR and the
microRNA binding sites, and had its own promoter that was not
subject to the complicated controls regulating expression of the
endogenous c-myb gene. It also expressed a c-Myb cDNA, so could
not generate the many alternative splicing isoforms that are
encoded by the normal c-myb gene. As shown in Figure 5A,
immunoprecipitation with anti-FLAG or anti-Myb antibodies,
Figure 2. Chromatin-associated levels of c-Myb remain con-
stant during the cell cycle. (A) Cell cycle sorting of formaldehyde
fixed cells. Asynchronously growing Jurkat cells were fixed with
formaldehyde, stained with Hoechst 33342 then subjected to cell
sorting, using a sorter equipped with a UV laser. The top panel shows
the original cell cycle distribution and the gates that were used to
collect the three cell cycle fractions. The lower panel shows the results
of re-analyzing the cells collected in each sorted fraction. (B) Jurkat cell
cycle analysis. Cell cycle histogram of a representative culture of Jurkat
T cells progressing through the cell cycle. The cells were fixed with
formaldehyde, stained with Hoechst 33342 and analyzed by flow
cytometry. The fraction of cells in each cell cycle phase is indicated at
the top. (C) Expression of c-Myb. Jurkat cells were fixed, stained with
Hoechst 33342 and sorted into G1, S or G2/M fractions. Total chromatin
was prepared from equal numbers of cells in each cell cycle fraction,
then the cross-links were reversed and the samples were analyzed by
Western blot (D) for expression of c-Myb protein. The blot was stripped
and re-probed for histone H4 as a loading control. Note: The
experiments in this figure were performed at least twice. The results
shown are from a single experiment but are representative of all the
trials.
doi:10.1371/journal.pone.0017362.g002
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that the FLAG-tagged derivative was stably expressed and ran
slightly higher on the gels than the endogenous c-Myb protein, due
to the FLAG epitope tag.
Using the cells that stably expressed the FLAG-tagged c-Myb,
we repeated the Fix-Sort-ChIP experiments described above, but
used anti-FLAG antibodies in the ChIP assays. As shown in
Figure 5B, the FLAG-tagged c-Myb was associated with the
CCNB1 promoter in G1 and more so in G2/M phase cells, but
not in S phase cells. This is very similar to the results obtained with
the endogenous c-Myb protein, using anti-Myb antibodies in the
ChIP assay (Figure 3A). The FLAG-tagged c-Myb also mimicked
endogenous c-Myb with CCNE1, binding only in G2/M phase
cells (Figure 5C), and with CXCR4, binding in both S phase and
G2/M, but not in G1 phase cells (Figure 5D).
The results with the ectopically expressed, FLAG-tagged c-Myb
are important because they provide evidence of what mechanisms
may be responsible for the retargeting of c-Myb during the cell
Figure 3. Redistribution of c-Myb during the cell cycle. Jurkat
cells were fixed with formaldehyde, stained with Hoechst 33342,
fractionated into cell cycle fractions by fluorescence-activated cell
sorting, then chromatin from equal numbers of cells in different cell
cycle fractions was analyzed by ChIP using anti-Myb antibodies. The
association of c-Myb with known target genes (A) CCNB1, (B) CCNE1 or
(C) CXCR4 is shown. Results are expressed as fold enrichment relative to
control IgG, and normalized to a control site in the GAPDH promoter, to
which c-Myb does not bind. Error bars show standard deviation of
triplicate QPCR reactions. These results are representative of several
independent experiments. Note: The experiments in this figure were
performed more than five times and two different anti-Myb antibodies
were used for the ChIP assays, which gave similar results. The results
shown are from a single experiment but are representative of all the
trials.
doi:10.1371/journal.pone.0017362.g003
Figure 4. Expression of cyclin target genes correlates with c-
Myb binding. Asynchronously growing Jurkat cells were collected,
stained and sorted into G1 or combined S/G2/M phase fractions, then
RNA was isolated and analyzed for the expression of the (A) CCNB1 or
CXCR4 or (B) CCNE1 gene mRNAs using quantitative real-time PCR. The
results were normalized to housekeeping genes GAPDH and PPIA and
to the expression levels detected in the asynchronously growing cells,
which were arbitrarily set to 1.0. Note: The experiments in this figure
were performed at least twice. The results shown are from a single
experiment but are representative of all the trials.
doi:10.1371/journal.pone.0017362.g004
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expression must not play a role, and the results cannot be due
to different activities of variant isoforms produced through
alternative RNA splicing, since the lentivirus vector expresses
only a single, full-length cDNA of c-Myb and is not subject to the
controls that regulate c-myb gene expression. Furthermore, the
microRNAs that control the stability and translation of c-myb
mRNA do not affect the lentivirus-expressed form, which lacks the
normal c-myb 39-UTR. Since these experiments used the anti-
FLAG antibodies, they also rule out the possibility that the results
with the anti-Myb antibodies were due to epitope masking or some
other antibody-specific effect. We conclude that this experiment
rules out all but post-translational mechanisms, such as changes in
post-translational modifications or protein-protein interactions in
regulating which genes c-Myb associates with during different
phases of the cell cycle.
Cell cycle dependent targeting of c-Myb also occurs in
primary cells and leukemias
All of the experiments we have reported so far were performed
with Jurkat T-cells, a long-established, immortalized cell line that
expresses relatively high levels of c-Myb [5,22]. Although Jurkat
cells are a good model for c-Myb in leukemias, which often have
rearranged or over-expressed c-myb genes [26], there was a
possibility that the cell cycle-dependent results were due to some
Jurkat cell-specific regulatory process. Therefore, we analyzed two
primary cell models with unique c-Myb target genes to rule out
that the cell cycle dependent changes we had observed were
somehow specific to T-cells or Jurkat cells.
First, we used the Fix-Sort-ChIP approach to assess the
association of c-Myb with the promoter of the KIT gene in
primary human CD34+ hematopoietic progenitors. Several
reports have implicated c-Myb as a bona fide regulator of the
KIT gene, which encodes the c-Kit cell surface receptor of Stem
Cell Factor or SCF [28–30]. Hematopoietic progenitor cells
express c-Kit on their cell surface and can be stimulated to
proliferate by culturing them in the presence of the c-Kit ligand
SCF [31]. The primary CD34+ hematopoietic progenitor cells
were fixed then stained with Hoechst 33342 and sorted into G1 or
a combined S/G2/M fraction. As shown in Figure 6A, approx-
imately 62% of the cells were in the G1 phase, and the rest were in
the S/G2/M fraction. When equal numbers of cells were analyzed
by ChIP assay, c-Myb was only found associated with the KIT
gene promoter in the G1 cells, and not in the S/G2/M cells
(Figure 6B). This is a striking result showing that c-Myb is specific
for some genes, in this case KIT, only in specific phases of the cell
cycle, even in primary hematopoietic progenitor cells.
We also used the Fix-Sort-ChIP approach to analyze c-Myb
association with target genes in primary human acute myeloid
leukemia (AML) samples. Here, we again assayed the association
of c-Myb with the CXCR4 gene, whose expression has been
implicated in poor prognosis in AML [32,33]. In this case, a vial of
cryopreserved bone marrow cells from an adult AML patient was
thawed and immediately fixed with formaldehyde, then the cells
were stained with Hoechst 33342, sorted into the G1 or S/G2/M
phase samples, and then equal numbers of cells from the two
fractions were subjected to ChIP analysis. As shown in Figure 6C,
nearly all the AML cells were in the G1 (or G0) phase of the cell
cycle. However, c-Myb associated with the CXCR4 gene
promoter exclusively in the cells that were in the S and/or G2/
M phase (Figure 6D). This echoes the result obtained with Jurkat
cells, in which c-Myb associated with the CXCR4 gene promoter
in both S and G2/M phase cells, but not G1 phase cells. Again,
this highlights the fact that samples can contain small subpopu-
Figure 5. FLAG-tagged c-Myb is also repositioned during the
cell cycle. (A) Expression of FLAG epitope-tagged c-Myb. Whole cell
extract (Input) from Jurkat cells stably expressing FLAG-tagged c-Myb
were subjected to immunoprecipitation using anti-FLAG or anti-Myb
antibodies, then the recovered proteins were analyzed by Western
blotting using anti-Myb antibodies. Stably-transduced Jurkat cells
expressing FLAG epitope-tagged c-Myb were fixed and sorted and
equal numbers of cells from the asynchronous (Asyn) population or the
G1, S or G2/M cell cycle fractions were subjected to ChIP assays as
described in Figure 4, using anti-FLAG or IgG (control) antibodies.
Quantitative real-time PCR assays were used to measure the enrichment
of the (B) CCNB1 and (C) CCNE1 or (D) CXCR4 gene promoters. Error bars
show standard deviation from triplicate QPCR reactions, and results are
typical of multiple experiments. Note: The experiments in this figure
were performed at least twice. The results shown are from a single
experiment but are representative of all the trials.
doi:10.1371/journal.pone.0017362.g005
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M phase of the cell cycle, which have dramatically different
properties, or in which c-Myb is associated with totally different
sets of target genes. Based on these results, we conclude that c-Myb
is bound to specific genes in distinct phases of the cell cycle,
suggesting that its ability to bind stably to promoters depends on
cell cycle-specific changes in protein-protein interactions.
Discussion
We have described the novel combination of cell fixation, cell
sorting and chromatin immunoprecipitation (Fix-Sort-ChIP assay)
as a means of following the localization of transcription factors, in
this case c-Myb, during different phases of the cell cycle. The Fix-
Sort-ChIP approach expands the usefulness of ChIP assays for the
analysis of subsets of cells within a population. The use of fixed
cells for cell sorting preserves the integrity of the chromatin
complexes during the cell sorting, which can take hours if small
subpopulations of cells are being purified. We also showed that
FLAG epitope-tagged c-Myb repositioned in the same manner as
the endogenously expressed protein. These results ruled out a
number of regulatory mechanisms that could be affecting c-Myb
specificity during the cell cycle, and opened the door for future
structure-function studies aimed at defining the elements and
domains within the c-Myb protein that control its activity and
specificity during the cell cycle.
Perhaps the most striking result from our Fix-Sort-ChIP assays
was the realization that c-Myb activity and specificity changed so
dramatically in subpopulations of cells in different phases of the
cell cycle. For example, in Jurkat cells, c-Myb associated with the
promoter of the Cyclin E1 gene (CCNE1) only in G2/M phase
cells. However, Western blots showed that the protein was
expressed at equal levels in the different cell cycle fractions. Thus,
c-Myb appeared to be targeted to specific promoters in distinct
phases of the cell cycle. Our results cannot distinguish whether the
access of c-Myb to the CCNE1 promoter is blocked in G1 and S
phase cells, or whether some change at the CCNE1 promoter in
G2/M phase cells allowed the c-Myb protein to form a stable
complex. However, the association of c-Myb with the CCNE1
promoter must be dynamic: the complex must be stabilized during
G2/M and de-stabilized in other parts of the cell cycle. Similarly
dramatic differences were observed in CD34+ hematopoietic
progenitors and in primary human AML samples, where c-Myb
associated only with the KIT gene in G1 phase cells and only with
Figure 6. Cell cycle specific targeting of c-Myb in primary cells and leukemias. (A) Cell cycle histograms of primary CD34+ cells that were
fixed and sorted into G1 or S/G2/M cell cycle fractions. The percentage of cells in each fraction is indicated at top. (B) Chromatin was prepared from
equal numbers of CD34+ cells that were fixed and sorted into the G1 or S/G2/M fractions and used for ChIP assays as described in Figure 3, using anti-
Myb antibodies. QPCR assays were used to measure enrichment of the KIT gene promoter. Results are relative to enrichment of a control region of
the GAPDH gene to which c-Myb does not bind. Error bars show standard deviation of triplicate QPCR assays. (C) Cell cycle histogram of
cryopreserved, primary human AML cells that were thawed and immediately fixed with formaldehyde, stained with Hoechst 33342 and sorted into G1
or S/G2/M fractions. (D) Equal numbers of sorted AML cells from each fraction were used to prepare chromatin and perform ChIP assays using anti-
Myb antibodies. QPCR was used to measure the enrichment for the CXCR4 gene promoter, as described in Figure 3. Results are relative to enrichment
of a control region of the GAPDH gene to which c-Myb does not bind. Error Bars show standard deviation of triplicate QPCR reactions. Note: The
experiments in this figure were performed at least twice, using cells from two different donors or patients, and all gave similar results. The results
shown are from a single experiment but are representative of all the trials.
doi:10.1371/journal.pone.0017362.g006
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dramatic cell cycle-dependent repositioning of c-Myb is not
limited to Jurkat cells, but also occurs in primary cells and
leukemias.
The DNA binding domain of c-Myb is highly conserved
amongst vertebrates and even insects and plants [34,35], and is
presumed to control the specificity of c-Myb by recognizing and
forming stable complexes at the appropriate promoters. However,
the c-Myb transcription factor recognizes a relatively simple
sequence motif, (C/T)AAC(G/T)G [1,36] which is expected to
occur on average about once per kilobase, or approximately three
million times in the human genome. Clearly, other determinants
such as combinatorial protein-protein interactions must play
important roles in regulating the specificities of transcription
factors like c-Myb [37]. But protein interactions are regulated
dynamically, through post-translational modifications and other
mechanisms, suggesting that the specificity of DNA binding
transcription factors like c-Myb, and the set of target genes that it
binds to, could change rapidly in a time-dependent manner.
The cell cycle regulation of c-Myb is reminiscent of NF-Y, the
ubiquitously expressed transcription factor that binds CCAAT-
box promoter elements [38,39]. NF-Y, which has histone-like
subunits, displaces nucleosomes from multimeric CCAAT-boxes
at the promoters it regulates and stimulates histone acetylation and
gene activation [40,41]. The c-Myb transcription factor is also
involved in chromatin remodeling, via its Myb/SANT domain,
which is related to components of chromatin remodeling
complexes [42,43]. The c-Myb Myb/SANT domain binds to
histone tails and promotes their acetylation, stimulating the
remodeling of chromatin and gene activation [44]. Thus, NF-Y
and c-Myb may share the ability to initiate the remodeling of
chromatin and the activation of cell cycle regulated genes.
A major unanswered question concerns how c-Myb and NF-Y
become targeted to the appropriate promoters at the correct times
in the cell cycle. NF-Y regulates different classes of promoters at
different times in the cell cycle, but it is thought to activate
constitutively: the actual cell cycle-dependent regulation occurs
through other factors, like E2F, that repress or activate the
promoters to which NF-Y is bound at specific times in the cell
cycle [45]. In contrast, the regulation and specificity of c-Myb
appears to be regulated during the cell cycle and may be linked to
its interactions with Cyclin D1/CDK complexes, since phosphor-
ylation at specific residues could change the affinity of c-Myb for
promoters by altering its ability to interact in a combinatorial
fashion with other proteins [37]. Several types of evidence have
shown that the specificity of c-Myb can be affected by mutations
[2,3,12] and that c-Myb regulates completely different sets of
target genes in different cell types [3,19], suggesting that its
specificity is controlled by interactions with other proteins. Our
new results suggest that these interactions and the activities of c-
Myb are not only tissue-specific, but also change dynamically
during the cell cycle.
A final question is whether the changing specificity of c-Myb is
linked to its potential oncogenic activity. We have shown that the
mutations that render c-Myb oncogenic also completely change its
specificity, leading to the activation of different sets of target genes
[2,3]. Our discovery of cell cycle specific changes in c-Myb activity
raise the possibility that oncogenic versions of c-Myb may
transform cells by regulating some target genes in the incorrect
stage of the cell cycle, which could stimulate cell cycle progression
or inactivate cell cycle checkpoints. There is evidence that
oncogenic versions of c-Myb push transformed cells through the
cell cycle, even in the absence of mitogenic growth factor signals
[46]. There is also a difference in the interactions between Cyclin
D1 and normal or oncogenic versions of c-Myb [4]. Thus,
oncogenic versions of c-Myb may have altered cell cycle-
dependent activities, which could be the key to their transforming
activities. Although our results demonstrate that c-Myb must
relocate to different genes in different parts of the cell cycle, we
have only analyzed a few target genes. It will be necessary to
extend the Fix-Sort-ChIP approach to genome-wide assays to
determine how general this relocating is and to identify the subsets
of target genes that c-Myb regulates in different stages of the cell
cycle.
Materials and Methods
Cells and Culture Conditions
Human Jurkat T-cells (#TIB152, ATCC Manassas, VA) were
cultured at 37u/5% CO2 in RPMI + Glutamax medium
(Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal
bovine serum (Invitrogen, Carlsbad, CA). Cytokine-mobilized
CD34+ cells (Fred Hutchison Cancer Research Center Large-
Scale Cell Processing Core) were cultured in IMDM media
(Invitrogen, Carlsbad, CA) supplemented with BITS serum
substitute, IL-3 (20 ng/ml), IL-6 (20 ng/ml), Stem Cell Factor
(100 ng/ml), and FLT-3 ligand (100 ng/ml) (all from Stem Cell
Technology, Vancouver, Canada).
Cell cycle Analyses
Cells were stained with 10 mg/ml Hoechst 33342 (Invitrogen,
Carlsbad CA) as described [47]. Alternatively, cells were seeded at
5610
5/ml and treated with 1 mg/ml nocodazole (Sigma, St Louis
MO) or 1 mM hydroxyurea (Sigma, St Louis MO) for 16–18 hr.
Western blot assays to measure Myb protein levels and
quantitative real time PCR assays for RNA levels were performed
as described previously [3,22]. RNA was isolated from equal cell
numbers with RNeasy Kit (Qiagen, Valencia CA) according to
manufacturer’s protocol and reverse transcribed (3 ug) into cDNA
template with Reverse Transcriptase III (Invitrogen, Carlsbad
CA). Taqman (Applied Biosystems, Foster City, CA) real time
PCR was used (except for CCNE1, SYBR green was used) to
analyze the expression of c-myb, CCNB1, CCND1, and PPIA. For
protein expression, formaldehyde-fixed proteins were extracted
and purified by hydroxyapatite chromatography [48]. Briefly, cells
were lysed in lysis buffer (5 M Urea, 2 M guanidine hydrochlo-
ride, 200 mM potassium phosphate buffer, and 2 M NaCl
supplemented with 1 mM chymostatin, leupeptin, antipain,
pepstatin-A, 1 mM each phenylmethylsulfonyl fluoride and
benzamidine), incubated on pre-equilibrated hydroxyapatite beads
(Biorad, Hercules, CA), de-crosslinked at 65u for 5 hours, and
precipitated with chloroform: methanol (1:4) before analysis by
Western blot. Cell cycle data was analyzed using FloJo software v
9.2.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed by slightly modifying standard
methods [49]. Briefly, approximately 1610
6 cells were resus-
pended in 500 ml of cell lysis buffer (20 mM Tris-HCl pH 8.0,
85 mM KCl, 0.5% NP-40 plus protease inhibitors mix: 1 mM
each of chymostatin, leupeptin, antipain and Pepstatin A and
1 mM each of Phenylmethanesulfonyl fluoride and benzamidine,
all from Sigma-Aldrich, St. Louis MO), incubated on ice for
10 min then lysed by passing up and down 2x through a 26 G
needle. The nuclei were recovered by centrifugation for 10 min at
14,0006g and resuspended in 100 ml of 50 mM Tris-HCl pH 8.0
containing 5 mM CaCl2 plus protease inhibitors. The chromatin
was sheared by adding 6 U of micrococcal nuclease (USB,
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10 mM and SDS to 1% and by heating to 65uC for 5 min to stop
the reaction. The tubes were vigorously mixed for 5 min at 4uC,
then centrifuged again to remove the debris. The supernatants
containing chromatin fragments were recovered and diluted 10-
fold with IP dilution buffer (0.01% SDS, 1.1% NP40, 1.2 mM
EDTA, 16.7 mM Tris-HCl pH 8.0, 167 mM NaCl plus protease
inhibitors). Antibodies were added and incubated overnight.
Immunoprecipitates were collected by adding protein A/G
agarose (30 ml) (Santa Cruz Biotechnology, Santa Cruz, CA) for
30 minutes at 4uC. The agarose: antibody complexes were
harvested by centrifugation and washed twice for 5 min each with
low salt buffer (0.1% SDS, 1%Triton X-100, 2 mM EDTA,
10 mM Tris-HCl pH 8.0, 150 mM NaCl, plus protease inhibi-
tors), high salt buffer (same as low salt buffer but 500 mM NaCl),
LiCl2 buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM
EDTA, 1% NP40, 1% Deoxycholate plus protease inhibitors) and
then TE (10 mM Tris-HCl pH 7.4, 1 mM EDTA plus protease
inhibitors). The beads were resuspended in 100 ml of 1% SDS plus
protease inhibitors and incubated 5 min at 65uC to elute the
immunoprecipitates. The samples were centrifuged and the
supernatants were transferred to new tubes, NaCl was added to
a final concentration of 0.3 M and they were incubated at 65uC
overnight to reverse the crosslinks. Then the samples were mixed
with 2.5 volumes of cold ethanol, incubated at 220uC for 2 hr and
centrifuged for 10 min at 14,0006 g to collect the DNA pellet,
which was rinsed with 70% ethanol, re-centrifuged, drained and
resuspended in 100 ml of 10 mM Tris-HCl pH 8.0. The samples
were supplemented with 1 ml Proteinase K (10 mg/ml, Sigma-
Aldrich) and 1 ml RNase A (100 mg/ml, Sigma-Aldrich) and
incubated at 42uC for 2 hr. The final DNA sample was purified
using a Qiagen MinElute PCR Purification Kit, following the
manufacturer’s instructions, and samples of the final product were
assayed by quantitative real-time PCR using gene-specific primer
sets (Table S1). ChIP was performed with anti-Myb monoclonal
1.1 antibodies (Millipore, Billerica MA), control non-immune
serum (10 ml), anti-FLAG (Sigma, St. Louis MO) or with a rabbit
anti-peptide antiserum prepared by using a peptide
(HQGTILDNVKNLLEFAE) from the c-Myb transcriptional
activation domain as antigen (Ab 1493). In the Jurkat cell assays,
these two antibodies gave very similar results, although only the
data obtained with the commercial antibodies are presented here.
Fix-Sort-ChIP Assay
The Fix-Sort-ChIP method combines fixation for chromatin
immunoprecipitation and cell cycle specific flow sorting tech-
niques, and is based on previously published methods [49], but the
complete procedure is provided here for clarity. Jurkat cells
(ATCC) were cultured in RPMI medium supplemented with 10%
fetal bovine serum (Invitrogen, Carlsbad CA). Approximately
1610
7 asynchronously growing cells were fixed by adding 1%
formaldehyde directly to the growth medium for 10 min. The
excess formaldehyde was quenched by adding Glycine to 0.125 M
for 5 min prior to harvesting the cells by centrifugation. The cells
were washed in PBS then resuspended at a density of 1610
6 per
ml in PBS containing 10 mg/ml Hoechst 33342 DNA content dye
(Invitrogen, Carlsbad CA) and incubated for 30 minutes at 37uC
[47]. After fixation, the cells were centrifuged and resuspended in
1 ml of growth medium containing 10 mg/ml Hoechst 33342 dye.
Fixed and stained cells were sorted using a MoFlo cell sorter
(Beckman Coulter, Fullerton CA). Hoechst fluorescence was
excited with UV wavelengths of an argon ion laser (40 mw,
351–368 nm multiline) and detected at 390–420 nm (405/30
band pass filter). Cells were electronically gated on forward and
side scatter signals excited by a second argon ion laser tuned to
488 nm to eliminate debris. An additional electronic gate was
constructed about the diagonal region of a dot plot of pulse area vs
pulse height for Hoechst fluorescence emission signals to eliminate
off-diagonal events corresponding to doublets and higher order
aggregates. Sorting was performed in single drop, purify mode to
achieve maximal purity of fractions, based on DNA content.
Sorted fractions were centrifuged and the cell pellets were stored at
280uC.
For chromatin immunoprecipitation, approximately 1610
6 cells
from each sorted cell cycle fraction were resuspended in 500 mlo f
cell lysis buffer (20 mM Tris-HCl pH 8.0, 85 mM KCl, 0.5% NP-
40 plus protease inhibitors mix: 1 mM each of chymostatin,
leupeptin, antipain and Pepstatin A and 1 mM each of
Phenylmethanesulfonyl fluoride and benzamidine, all from
Sigma-Aldrich, St. Louis MO), incubated on ice for 10 min then
lysed by passing up and down 2x through a 26 G needle. The
nuclei were recovered by centrifugation for 10 min at 14,000
RPM in the microcentrifuge and resuspended in 100 mlo f5 0m M
Tris-HCl pH 8.0 containing 5 mM CaCl2 plus protease inhibitors.
The chromatin was sheared by adding 6 U of micrococcal
nuclease (USB, Cleveland OH) for 10 min at 37uC, followed by
adding EDTA to 10 mM and SDS to 1% and by heating to 65uC
for 5 min to stop the nuclease reaction. The tubes were placed on
a vortex mixer for 5 min at 4uC, then centrifuged 10 min at top
speed in the microcentrifuge (14,000 RPM) to remove the debris.
The supernatants containing chromatin fragments were recovered
and diluted 10-fold with IP dilution buffer (0.01% SDS, 1.1%
NP40, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.0, 167 mM
NaCl plus protease inhibitors as described above). Antibodies were
added and incubated overnight. Immunoprecipitates were col-
lected by adding protein A/G agarose (30 ml) (Santa Cruz
Biotechnology, Santa Cruz, CA) for 30 min at 4uC. The agarose:
antibody complexes were harvested by centrifugation and washed
2 times for 5 min each with low salt buffer (0.1% SDS, 1%Triton
X-100, 2 mM EDTA, 10 mM Tris-HCl pH 8.0, 150 mM NaCl,
plus protease inhibitors), high salt buffer (same as low salt buffer
but 500 mM NaCl), LiCl2 buffer (10 mM Tris-HCl pH 8.0,
250 mM LiCl, 1 mM EDTA, 1% NP40, 1% Deoxycholate plus
protease inhibitors) and then TE (10 mM Tris-HCl pH 7.4, 1 mM
EDTA plus protease inhibitors). The beads were resuspended in
100 ml of 1% SDS plus protease inhibitors and incubated 5 min at
65uC to elute the immunoprecipitates. The samples were
centrifuged and the supernatants were transferred to new tubes,
NaCl was added to a final concentration of 0.3 M and then they
were incubated at 65uC overnight to reverse the cross-links. Then
the samples were mixed with 2.5 volumes of cold ethanol,
incubated at 220uC for 2 hr and centrifuged for 10 min in the
microcentrifuge (14,000 RPM) to collect the DNA pellet, which
was rinsed with 70% ethanol, re-centrifuged, drained and
resuspended in 100 ml of 10 mM Tris-HCl pH 8.0. The samples
were supplemented with 1 ml Proteinase K (10 mg/ml, Sigma-
Aldrich) and 1 ml RNase A (100 mg/ml, Sigma-Aldrich) and
incubated at 42uC for 2 hr. The final DNA sample was purified
using a Qiagen MinElute PCR Purification Kit, following the
manufacturer’s instructions, and samples of the final product were
assayed by quantitative real-time PCR using gene-specific primer
sets (Table S1).
Myb Lentivirus Vector
The cDNA encoding an N-terminal FLAG-tagged human c-
Myb [3] was cloned into the unique PacI site of the pHR IRES
GFP lentiviral vector (kindly provided with packaging vectors by
Dr. Bruce Bunnell, Tulane University) directly downstream of the
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produced by calcium phosphate transient transfection of 293 FT
cells (Invitrogen, Carlsbad CA) along with the lentiviral packaging
plasmid delta 8.9 and the pMD.G plasmid expressing the vesicular
stomatitis virus glycoprotein. Cell culture supernatant was
collected twice in 24 hr intervals post transfection and viral
supernatant was concentrated by ultrafiltration using an Ambion
Ultracell 100 kDa NMWL filter unit (Millipore, Billerica MA).
Jurkat cells were transduced in the presence of 8 mg/ml of
polybrene (Sigma, St. Louis MO) and GFP+ cells were recovered
by cell sorting.
Supporting Information
Table S1 Real time PCR primer pairs. The table describes
the primer pairs used for Quantitative Real Time PCR (QPCR)
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